Skip to main content

Talk Bio

Search This Blog

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on July 24, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Scribe Therapeutics Inc. raised approximately $128.7 million in an upsized initial public offering (IPO), paving the way for its shares to begin trading on the Nasdaq Global Market under the ticker symbol SCTX on July 24, 2026.

The company sold 8.58 million shares at $15 apiece, topping the previously marketed range of $13 to $15.

Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based gene therapies for cardiometabolic diseases, with its lead asset STX-1150 targeting PCSK9 for lowering LDL cholesterol.

The IPO is notable as one of the first gene-editing company IPOs in more than two years, signaling renewed investor interest in early-stage biotech and gene-editing platforms.

Sources:

Scribe Therapeutics Submits IPO Filing for CRISPR-Based PCSK9 ...

Eli Lilly-Backed Scribe Raises $128.7 Million in Upsized IPO

Scribe Therapeutics Files Nasdaq IPO With $180M - allsci.com

Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase

Scribe Therapeutics’ $100M IPO Is the First Public “Pure-Play CRISPR Risk Read” of 2H 2026—And It’s Valuing Epigenetic Gene Editing Like a Clinical-Stage Bet | Plutux Insights

Scribe secures $129M in a rare gene editing IPO

Scribe Therapeutics Files for Nasdaq IPO Under SCTX

Cardiovascular diseases biotech Scribe Therapeutics files for ...

With first clinical data due next year, Scribe to test IPO market

Scribe Therapeutics prices upsized IPO at $15 per share, ...

Scribe aims for $96M IPO to fund lipid-lowering genetic meds

Scribe Therapeutics Files IPO

Top Stock Alerts

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

cardiometabolic Clustered Regularly Interspaced Short Palindromic Repeats eli lilly gene editor IPO sanofi Scribe Therapeutics SCTX STX-1150

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC